|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.
|
31123029 |
2020 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
At present, a few STAT5 inhibitors are in phase I or II clinical trials for the treatment of leukemias and graft vs host disease.
|
31490767 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data define STAT5B as major STAT5 isoform driving BCR/ABL<sup>+</sup> leukemia.
|
30679796 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-γ (PPARγ) agonist pioglitazone downregulates signal transducer and activator of transcription 5 (STAT5) and in combination with imatinib induces complete molecular response in imatinib-refractory patients by eroding leukemia stem cells.
|
31371410 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
STAT5A and STAT5B-Twins with Different Personalities in Hematopoiesis and Leukemia.
|
31690038 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, our results demonstrate that STAT5, in part by upregulating PIM1 activity, plays a major role in mediating the leukemia-promoting effects of IL-7/IL-7R.
|
30185437 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
By doing so, STAT5 activation promotes an overall elevation of ROS level, which acts as a feed-forward loop, especially in high risk Fms-related tyrosine kinase 3 (FLT3) mutant leukemia.
|
30262727 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.
|
28369050 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The constitutive activation of signal transducer and activator of transcription 5 (STAT5) occurs during the transformation of fusion genes in leukemia.
|
26384082 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that mouse thymic stromal lymphopoietin does not stimulate the downstream pathways (JAK/STAT5 and PI3K/AKT/mTOR) activated by the human cytokine in primary high-risk leukemia with overexpression of the receptor component.
|
26611474 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that combining kinase inhibition with STAT5 inhibition represents a promising therapeutic approach in BCR-ABL1+ leukemias.
|
24813920 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In experimental models of acute T-cell lymphoblastic leukemias, where activated STAT5 contributes to leukemia cell survival, Brd2 knockdown or JQ1 treatment shows strong synergy with tyrosine kinase inhibitors (TKI) in inducing apoptosis in leukemia cells.
|
24435449 |
2014 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicate that the inhibition of STAT5 by IL-1β may be a promising treatment strategy to eradicate leukemia stem cells in AML.
|
23564444 |
2013 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To search for these molecules we aligned IL-2 regulated genes detected by Affymetrix gene expression microarrays with the STAT5 cistrome identified by chip-on-ChIP analysis in an IL-2-dependent human leukemia cell line, Kit225.
|
23451206 |
2013 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genotype analyses showed that two SNPs, namely rs17886724 and rs2293157 located in STAT3 and STAT5, respectively, were significantly associated with leukemia (p < 0.05 for all).
|
22126101 |
2012 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results demonstrate that STAT5a/b is essential for the induction of CML-like leukemia by BCR-ABL1 and of polycythemia by JAK2(V617F), and validate STAT5a/b and the genes they regulate as targets for therapy in these MPNs.
|
22234689 |
2012 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
It also suggests that STAT5 may serve as an attractive target to overcome imatinib resistance in BCR-ABL1(+) leukemia.
|
21220747 |
2011 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study investigated the potential therapeutic effect of STAT5 decoy oligodeoxynucleotides (ODN) using leukemia K562 cells as a model.
|
21091189 |
2011 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, interference with Stat5a serine phosphorylation might provide a new therapeutic option for leukemia and myeloid dysplasias without affecting major functions of Stat5 in normal hematopoiesis.
|
20508164 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
STAT5 in B cell development and leukemia.
|
20227268 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal.
|
19667399 |
2009 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
One possible pathomechanism causing leukemia is that clones of cells harboring acquired CSF3R mutations have a growth advantage over wild type cells in vivo during granulocyte-colony stimulating factor treatment due to activation of STAT5 and ss-catenin, both known to be involved in leukemogenesis.
|
18536571 |
2008 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of Stat5A in mammary gland carcinoma and leukaemia has already been reported.
|
16303247 |
2006 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
STAT5 (signal transducers and activators of transcription) are suggested to play a role in the pathogenesis of leukaemia and lymphoma; however, their influence on the growth of cutaneous T-cell lymphoma cells is not clear enough.
|
16502315 |
2006 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, Stat5 tetramers were found to accumulate in excess compared to dimers in various human leukemias.
|
15652752 |
2005 |